PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

KDIGO 2026 Anemia in CKD Guideline: ESA First, Proactive IV Iron in Hemodialysis

KDIGO 2026 Anemia in CKDKDIGOanemiachronic kidney diseasehemodialysisintravenous ironESAHIF-PHIdaprodustatvadadustatRBC transfusion Nephrology / Renal Pharmacy

Background Information

Updated guidelines prioritize personalized anemia management in chronic kidney disease.

Anemia is a prevalent complication in chronic kidney disease (CKD) affecting patient outcomes and quality of life. The guideline updates include preference for intravenous iron in hemodialysis, individualized hemoglobin thresholds, and choosing erythropoiesis-stimulating agents over hypoxia-inducible factor-prolyl hydroxylase inhibitors. Reinforces dosing strategies focused on individual patient needs for anemia management in CKD, emphasizing safety and efficacy of therapies. Revised guidelines optimize anemia treatment in CKD with tailored iron and erythropoiesis-stimulating agent use.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Hedayati SS, Babitt JL, Berns JS, Bozkurt B, Cheung RS, Cuevas Y, Effa EE, Eisenga MF, Fishbane S, Ginzburg YZ, Haase VH, Kim S, Moura-Neto JA, Rossignol P, Sahay M, Tanaka T, Wang AY, Wheeler DC, Robinson KA, Wilson LM, Wilson RF, King JM, Earley A, Akl EA, Tonelli M, Nagler EV

Citation: Hedayati SS, Babitt JL, Berns JS, et al. Evaluation and Management of Anemia in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 Clinical Practice Guideline. Annals of internal medicine. 2026. doi:10.7326/ANNALS-26-02326

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.